文献速递毛发、甲与色素性疾病

非常规剂量托法替布与巴瑞替尼治疗儿童中重度斑秃的耐受性与疗效

Tolerability and efficacy of unorthodox dosing regimens of tofacitinib and baricitinib in pediatric patients with moderate to severe alopecia areata.
PubMed 文献 · J Am Acad Dermatol · 2025-10-10

这项随机对照研究纳入100例SALT评分21-100的儿童中重度斑秃患者,1:1分配至托法替布组(n=51)或巴瑞替尼组(n=49),评估24周非常规剂量下的耐受性与疗效。结果显示两组疗效相当且耐受性良好,无严重不良事件发生。

要点

  • 中度患者SALT≤10比例:托法替布33.33% vs 巴瑞替尼41.18%(P=.87)
  • 极重度患者SALT≤20比例:托法替布47.37% vs 巴瑞替尼31.58%(P=.51)
  • 两组均耐受良好,24周内无严重不良事件发生

核心结论

  • 非常规剂量的托法替布与巴瑞替尼在儿童中重度斑秃中24周疗效相当且耐受性良好,支持短期使用。

研究设计与样本

  • 随机对照研究,纳入100例SALT评分21-100的儿童中重度斑秃患者,1:1分配至托法替布组(n=51)或巴瑞替尼组(n=49),疗程24周。

主要发现

  • 中度患者达到SALT≤10的比例:托法替布33.33%,巴瑞替尼41.18%(P=.87)。
  • 重度患者达到SALT≤20的比例:托法替布45.45%,巴瑞替尼30.77%(P=.75)。
  • 极重度患者达到SALT≤20的比例:托法替布47.37%,巴瑞替尼31.58%(P=.51)。
  • 达到SALT90的比例:巴瑞替尼组36.73%数值上高于托法替布组21.57%(P=.16)。
  • 两组均耐受良好,无严重不良事件发生。

关键数值与推荐

  • 主要结局:中度患者第24周SALT≤10,重度及极重度患者第24周SALT≤20。
  • 中度患者SALT≤10:托法替布33.33% vs 巴瑞替尼41.18%(P=.87)。
  • 重度患者SALT≤20:托法替布45.45% vs 巴瑞替尼30.77%(P=.75)。
  • 极重度患者SALT≤20:托法替布47.37% vs 巴瑞替尼31.58%(P=.51)。
  • SALT90:巴瑞替尼36.73% vs 托法替布21.57%(P=.16)。

临床怎么用

  • 非常规剂量托法替布或巴瑞替尼可考虑用于儿童中重度斑秃的短期治疗。

局限性

  • 研究疗程短,疗效结果可能不适用于标准剂量方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Evidence on tofacitinib and baricitinib in pediatric alopecia areata is limited. OBJECTIVE: To evaluate the comparative tolerability and efficacy of tofacitinib and baricitinib with unorthodox dosing in pediatric moderate-to-severe alopecia areata over 24 weeks. METHODS: One hundred pediatric patients (severity of alopecia tool [SALT] score 21-100) were randomized 1:1 to tofacitinib (n = 51) or baricitinib (n = 49). PRIMARY OUTCOMES: SALT score ≤10 (moderate, 21-49) and SALT score ≤20 (severe, 50-94, and very severe, 95-100) at week 24. RESULTS: For moderate patients, 33.33% (tofacitinib) and 41.18% (baricitinib) achieved SALT score ≤10 (P = .87). For severe patients, 45.45% (tofacitinib) and 30.77% (baricitinib) achieved SALT score ≤20 (P = .75). For very severe patients, 47.37% (tofacitinib) and 31.58% (baricitinib) achieved SALT score ≤20 (P = .51). For secondary outcomes, the proportion of patients achieving SALT90 in the baricitinib group (36.73%) was numerically higher than that in the tofacitinib group (21.57%) (P = .16). Both were well-tolerated and no serious adverse events occurred. LIMITATIONS: Short duration and efficacy findings may not generalize to standard dosing regimens. CONCLUSIONS: Unorthodox-dosed tofacitinib and baricitinib showed comparable efficacy and were well-tolerated in pediatric alopecia areata over 24 weeks, supporting short-term use.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Wan M, Zhang M, Song X, et al. Tolerability and efficacy of unorthodox dosing regimens of tofacitinib and baricitinib in pediatric patients with moderate to severe alopecia areata. J Am Acad Dermatol. 2025. PMID: 41076129. doi:10.1016/j.jaad.2025.10.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。